Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0963 • ACR Convergence 2023
Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis
Maithri Aspari¹, Josephine Geertsen Keller-Socin¹, Stinne Greisen², Esben Naeser³, Klaus Soendergaard⁴, Birgitta R Knudsen⁵, Voon Ong⁶, Christopher Denton⁷, David Abraham⁷ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University/Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Institute for molecular Biology, Aarhus University, Aarhus, Denmark, ⁶UCL Medical School Royal Free Campus, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…
Abstract Number: 1961 • ACR Convergence 2023
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome
Matthew Sherman¹, Payam Noroozi Farhad², Edward Trieu³, Katherine Pak⁴, Iago Pinal-Fernandez⁴, Kakali Sarkar², Megan Neely⁵, Ira Targoff⁶, Frederick Miller⁷, Andrew Mammen⁸ and Lisa Rider⁹, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁶Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸NIH, Bethesda, MD, ⁹NIEHS, NIH, Bethesda, MD
Background/Purpose: Anti-PM/Scl autoantibodies (Abs) are an uncommon myositis-associated autoantibody (MAA) in juvenile myositis. The clinical features and outcomes associated with anti-PM/Scl Abs in juvenile myositis…
Abstract Number: 2510 • ACR Convergence 2023
Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
Tineke van Wesemael¹, Jessica Borgers², Kyra Gelderman³, Els Verdegaal⁴, C.M. Korse⁵, M.J.P. Welters⁶, Ellen Kapiteijn⁷, W.J. van Houdt², Sjoerd van der Burg⁶, René Toes¹, J.V. Thienen², John Haanen² and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Amsterdam, Netherlands, ⁵Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, Netherlands, ⁶Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: PD-1 immune checkpoint inhibitors are able to re-activate restrained anti-tumor T-cell responses in melanoma patients. However, PD-1 inhibition may also activate auto-reactive T-cells leading…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0659 • ACR Convergence 2023
Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort
Jacopo Ciaffi¹, Sophie Liem², Saad Ahmed², Eva Hoekstra², Piotr Wiland³, Tatsuya Atsuma⁴, Gabriella Szucs⁵, Alexandra Balbir-Gurman⁶, Laszlo Czirjak⁷, Elisabetta Zanatta⁸, Ina Koetter⁹, Joerg Henes¹⁰, marco Matucci Cerinic¹¹, Paolo Airò¹², Francesco Ursini¹³, Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Wroclaw University of Medicine, Wroclaw, Poland, ⁴Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁵University of Debrecen, Department of Rheumatology, Debrecen, Hungary, ⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁷Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ⁹University Hospital Eppendorf, Prisdorf, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany, ¹¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹²Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹³IRCCS Istituto Ortopedico Rizzoli, Bologna, Netherlands
Background/Purpose: In rheumatoid arthritis, cigarette smoking confers a risk for anti-CCP positive disease and the risk further increases in smokers carrying specific HLA DRB1-variants. These…
Abstract Number: 1138 • ACR Convergence 2023
Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies
Cristiana Sieiro Santos¹, Jose Luis Tandaipan², Anais Mariscal², Luis Sainz-Comas², Helena Codes², Patricia Moya², Berta Paula Magallares-Lopez³, Laura Martínez Martínez², Ana Milena Millán Arciniegas², Hye Sang Park², César Díaz-Torné², Ana Laíz Alonso², Susana Fernández², Sandra Ros², Hector Corominas⁴, Elvira Díez Álvarez⁵ and Iván Castellvi², ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ³Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ⁵CAULE, León, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful…
Abstract Number: 1597 • ACR Convergence 2023
Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus
Wangbin Ning, Gary Gilkeson and Wei Jiang, Medical University of South Carolina, Charleston, SC
Background/Purpose: There is an intricate interplay between the microbiome and the immune response impacting the development of normal immunity and autoimmunity. However, we do not…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 2578 • ACR Convergence 2023
Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles
Jenny Wei¹, Mark Tarnopolsky², Marie Hudson³, Ross Mitchell⁴, Katherine Buhler⁵, Antoine Dufour⁶, Luiz de Almeida⁶, Paul R. Fortin⁷, Eric Boilard⁸, Yann Becker⁸, Erin Hatcher², Mei Feng Zhang⁶, Marvin Fritzler⁶ and May Choi⁶, ¹University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁸Université Laval, Quebec City, QC, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…
Abstract Number: 0253 • ACR Convergence 2023
Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity
Ruoning Ni¹ and Petar Lenert², ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Anti-ribonucleoprotein (RNP) and anti-Sm/RNP common motif antibodies play a critical role in diagnosing patients with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)…
Abstract Number: 0665 • ACR Convergence 2023
A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody
Mridula Dilip¹, Maureen Laffoon², Yongseok Park³, Robert Lafyatis⁴, Thomas Medsger⁵, Virginia Steen⁶, Leigh Freno² and Robyn Domsic⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh School of Medicine, Verona, PA, ⁶Georgetown University School of Medicine, Washington, DC
Background/Purpose: U2RNP is a spliceosome-associated autoantibody that has in prior case reports presented with scleroderma with myositis (SSc/PM)and SLE overlap. Autoantibodies are growing in prognostic…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1972 • ACR Convergence 2023
Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Christina Charles-Schoeman¹, Joachim Schessl², Rohit Aggarwal³ and and the ProDERM investigators⁴, ¹UCLA Medical Center, Santa Monica, CA, ²Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…

« Previous Page
1
…
7
8
9
10
11
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].